Palvella Therapeutics (PVLA) Free Cash Flow (2013 - 2026)
Palvella Therapeutics (PVLA) reported Free Cash Flow of -$10.9 million for Q1 2026, down 61.05% year-over-year from -$28.0 million in Q1 2025, and down 121.54% quarter-over-quarter from -$4.9 million in Q4 2025.
Palvella Therapeutics (PVLA) Free Cash Flow (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has 14 years of Free Cash Flow data on file, last reported at -$10.9 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$10.9 million, down 61.05% year-over-year; the trailing twelve-month figure through Mar 2026 was -$29.1 million (down 76.49% YoY), and the FY2025 annual result was -$25.0 million, down 130.63% from the prior year.
- Free Cash Flow fell to -$10.9 million in Q1 2026 per PVLA's latest filing, from -$4.9 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $20.6 million in Q4 2023 and troughed at -$22.9 million in Q1 2022.
- A 5-year average of -$7.1 million and a median of -$7.9 million in 2025 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2023 and 2025: Free Cash Flow jumped 247.97% in 2023, then sank 514.16% in 2025.
- A 5-year view of Free Cash Flow shows it stood at -$13.9 million in 2022, then jumped by 247.97% to $20.6 million in 2023, then plunged by 126.14% to -$5.4 million in 2024, then climbed by 8.77% to -$4.9 million in 2025, then sank by 121.54% to -$10.9 million in 2026.
- Business Quant data shows PVLA's Free Cash Flow at -$10.9 million in Q1 2026, -$4.9 million in Q4 2025, and -$7.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Palvella Therapeutics | 1.49 Bn | 1.23 Bn | - | -10.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.90 Mn |
| Mar 31, 2026 | -10.90 Mn |
| Dec 31, 2025 | -4.92 Mn |
| Dec 31, 2025 | -4.92 Mn |
| Sep 30, 2025 | -7.88 Mn |
| Sep 30, 2025 | -7.88 Mn |
| Jun 30, 2025 | -5.43 Mn |
| Jun 30, 2025 | -5.43 Mn |
| Mar 31, 2025 | -6.77 Mn |
| Mar 31, 2025 | -6.77 Mn |
| Dec 31, 2024 | -5.39 Mn |
| Dec 31, 2024 | -5.39 Mn |
| Sep 30, 2024 | -2.74 Mn |
| Sep 30, 2024 | -2.74 Mn |
| Jun 30, 2024 | -1.60 Mn |
| Jun 30, 2024 | -1.60 Mn |
| Mar 31, 2024 | -1.10 Mn |
| Mar 31, 2024 | -1.10 Mn |
| Dec 31, 2023 | 20.63 Mn |
| Dec 31, 2023 | 20.63 Mn |